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INTRODUCTION 
An intranasal gel formulation of scopolamine (INSCOP) was developed for the treatment of Space Motion Sickness. 
The bioavailability and pharmacokinetics (PK) were evaluated under the Food and Drug Administration guidelines 
for clinical trials for an Investigative New Drug (IND). The aim of this project was to develop a PK model that can 
predict the relationship between plasma, saliva and urinary scopolamine concentrations using data collected from the 
IND clinical trial with INSCOP. 
 
METHODS 
Twelve healthy human subjects were administered three dose levels (0.1, 0.2 and 0.4 mg) of INSCOP. Serial blood, 
saliva and urine samples were collected between 5 min to 24 h after dosing and scopolamine concentrations 
measured by using a validated LC-MS-MS assay. Pharmacokinetic Compartmental models, using actual dosing and 
sampling times, were built using Phoenix (version 1.2). Model discrimination was performed, by minimizing the 
Akaike Information Criteria (AIC), maximizing the coefficient of determination (r²) and by comparison of the 
quality of fit plots.  
 
RESULTS 
The best structural model to describe scopolamine disposition after INSCOP administration (minimal AIC =907.2) 
consisted of one compartment for plasma, saliva and urine respectively that were inter-connected with different rate 
constants. The estimated values of PK parameters were compiled in Table 1. The model fitting exercises revealed a 
nonlinear PK for scopolamine between plasma and saliva compartments for K21, Vmax and Km.  
 
CONCLUSION 
PK model for INSCOP was developed and for the first time it satisfactorily predicted the PK of scopolamine in 
plasma, saliva and urine after INSCOP administration. Using non-linear PK yielded the best structural model to 
describe scopolamine disposition between plasma and saliva compartments, and inclusion of non-linear PK resulted 
in a significant improved model fitting. The model can be utilized to predict scopolamine plasma concentration 
using saliva and/or urine data that allows non-invasive assessment of pharmacotherapeutics of scopolamine in space 
and other remote environments without requiring blood sampling. 
 
Description Parameter 
Dose(mg) 
0.1 0.2 0.4 
Estimate CV% Estimate CV% Estimate CV% 
saliva compartment, elimination rate constant Ksout(hr-1) 0.4 35.1 0.7 164.8 0.6 108.6 
saliva to plasma rate constant K21(hr -1) 1.7 224.5 1.5 184.4 1.2 282.6 
plasma to saliva, maximum rate Vmax(ng/hr) 1768.0 121.1 1514.9 74.5 1696.1 137.7 
plasma to saliva, Michaelis-Menten constant Km(ng/ml)) 146.7 74.8 120.7 61.8 163.3 67.6 
plasma compartment, 1st order absorption rate constant  Ka (hr
-1) 0.3 88.2 0.5 73.5 0.3 39.3 
plasma compartment, elimination rate constant Kpout(hr-1) 0.9 68.1 0.7 60.3 0.4 241.5 
plasma to urine rate constant Kel(hr-1) 0.01 61.1 0.01 41.3 0.01 63.6 
                                                                             Table 1                                
https://ntrs.nasa.gov/search.jsp?R=20140013487 2019-08-31T17:22:15+00:00Z
